Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Status:
Terminated
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
Subjects who received tesevatinib in Study KD019-101 and completed 24 months of treatment
will continue on the dose of tesevatinib they were receiving at 24 months on the KD019-101
study.